Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Aprea Presents Preclinical Data at AACR

Published: Tuesday, April 08, 2014
Last Updated: Tuesday, April 08, 2014
Bookmark and Share
Data reveals that APR-246 resensitizes ovarian cancer cells to platinum compounds and doxorubicin.

Aprea AB has presented preclinical data at the American Association for Cancer Research (AACR) meeting in San Diego, USA. The data reveals that Aprea's candidate drug APR-246, a compound that reactivates mutant p53, is able to resensitize ovarian cancer cells to platinum compounds and doxorubicin.

A Phase Ib/II study with APR-246 in relapsed platinum sensitive ovarian cancer is currently open for recruitment. Aprea is part of the Karolinska Development portfolio.

Platinum-based drugs are since decades used as first-line treatment for many solid tumors. Patients with ovarian cancer often respond well to platinum compounds, but many of these patients develop resistance to platinum and die of chemotherapy refractory disease.

The mechanisms underlying resistance are multifactorial, but two of the main causes are mutations in the tumor suppressor protein p53 and elevated intracellular glutathione levels.

The preclinical data presented shows that APR-246 not only reactivates mutant p53, but also decreases intracellular glutathione levels in a dose-dependent manner. This unique mechanism of action, targeting both mutant p53 and glutathione, is likely to account for the strong synergistic effects of APR-246 and platinum drugs as well as resensitization of ovarian cancer cells, which were observed in the study.

“The results provide a strong rationale for the clinical trial in intermediate platinum resistant ovarian cancer and suggest that treatment with APR-246 in combination with platinum-based chemotherapy could have a broad applicability in the treatment of drug resistant p53 mutant human tumors”, comments Mikael von Euler, CMO of Aprea.

The title of Aprea’s poster presentation at AACR was “APR-246, a clinical-stage mutant p53-reactivating compound, resensitizes ovarian cancer cells to platinum compounds and doxorubicin”. The full abstract (Abstract # 1801), is available on

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aprea Presents Preliminary Clinical Phase Ib/II Results in Ovarian Cancer at AACR
Company presents results with APR-246 - a novel candidate drug that restores mutant p53 protein into its wild-type function.
Tuesday, April 21, 2015
Dosing Initiated in Phase I/II Clinical Trial of APR-246 in Ovarian Cancer
Promising data from trial has been presented in Journal of Clinical Oncology.
Thursday, April 17, 2014
Scientific News
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
GMO Food Animals Should be Judged by Product, Not Process
In a world with a burgeoning demand for meat, milk and eggs, regulatory policies around the use of biotechnologies in agriculture need to be based on the safety and attributes of those foods rather than on the methods used to produce them, says a UC Davis animal scientist.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
Gene Drive Reversibility Introduces New Layer of Biosafety
Ability to introduce or reverse the spread of genetic traits through populations could one day improve pest management and disease control.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos